Every Form 4 that Unicycive Therapeutics, Inc. (UNCY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UNCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNCY filings page.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. director Sara Kenkare-Mitra reported an equity compensation award of 47,941 Restricted Stock Units on May 14, 2026. The RSUs are payable solely in common stock; 19,976 shares vest immediately and 3,995 vest monthly over seven months from June 1, 2026, contingent on continued service.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. director Sandeep Laumas received a grant of 47,941 restricted stock units on May 14, 2026, payable solely in common stock.
Of these, 19,976 RSUs vest upon grant and 3,995 vest monthly over seven months beginning June 1, 2026, subject to his continued service; post‑grant holdings total 47,941 RSUs.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units (RSUs) payable in common stock. These RSUs are a form of equity compensation, not an open-market purchase or sale.
According to the award terms, 105,861 shares vest immediately upon grant. An additional 21,172 shares vest over 31 months beginning on June 1, 2026, contingent on Gupta’s continued service with the company. Following this grant, the Form 4/A shows Gupta holding 762,200 RSUs linked to common stock.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two new restricted stock unit (RSU) awards as equity compensation. On May 14, 2026, she was granted 42,100 RSUs and a separate 84,200 RSU annual award, each payable solely in common stock.
For the 42,100-unit RSU award, 11,694 shares vest immediately, with 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to her continued service. For the 84,200-unit annual RSU award, 17,542 shares vest upon grant and 3,508 vest monthly over 7 months starting the same date.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sandeep Laumas received two equity compensation grants in the form of restricted stock units (RSUs). The Form 4/A reports awards covering 42,100 and 84,200 RSUs, each payable solely in Unicycive common stock.
Footnotes explain that one RSU award provides 11,694 shares vesting upon grant and 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to his continued service. A second annual RSU award provides 17,542 shares vesting upon grant and 3,508 shares vesting monthly over 7 months beginning the same date, also contingent on continued service. These are compensation-related grants at a stated price of $0.00 per unit, not open‑market share purchases or sales.
Gupta Pramod reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that EVP, Pharmaceuticals and BD, Pramod Gupta received a grant of 169,500 restricted stock units (RSUs) payable solely in common stock. This is a compensation-related award, not an open-market share purchase or sale.
According to the award terms, 23,542 shares vest upon grant, and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, subject to Gupta’s continued service with the company. Following this grant, his reported derivative holdings from this RSU award total 169,500 underlying shares.
Townsend John reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) tied to the company’s common stock. This is a stock-based compensation award, not an open-market share purchase or sale.
According to the footnote, 23,542 shares vest upon grant, and an additional 4,708 shares vest over 31 months beginning on June 1, 2026, as long as he continues to serve at the company. Following this award, Townsend is shown as directly holding 169,500 RSUs, aligning his compensation more closely with the company’s future stock performance.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Douglas Jermasek received a grant of 169,500 restricted stock units payable in common stock. According to the award terms, 23,542 shares vest immediately on grant and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, contingent on continued service.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units. These RSUs are payable solely in common stock and vest in three equal installments on each anniversary of the grant date over three years, conditioned on his continued service with the company. Following this grant, Gupta is reported as holding 762,200 RSUs tied to an equal number of underlying common shares.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two equity awards in the form of restricted stock units. On May 14, 2026, she was granted 42,100 RSUs that vest in three equal annual installments and 84,200 RSUs that vest after one year, all settling in common stock and tied to continued service with the company. Following these grants, she holds 126,300 RSUs directly as part of her compensation, with no open-market share purchases or sales reported.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that EVP of Corporate Strategy Douglas Jermasek received a grant of 169,500 restricted stock units (RSUs) payable solely in common stock.
The RSU award vests in three equal installments, with 1/3 vesting on each anniversary of the grant date over three years, contingent on his continued service with the company. Following this grant, he is reported as holding 169,500 underlying shares tied to this RSU award.
Gupta Pramod reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Pramod Gupta received a grant of 169,500 restricted stock units (RSUs) payable in common stock. This equity award was granted at no cash cost to him and represents stock-based compensation rather than an open-market share purchase or sale.
According to the footnote, the RSU award vests in three equal parts: one-third on each anniversary of the grant date over three years, as long as Gupta continues his service with the company. Following this grant, he holds 169,500 RSUs directly, aligning his compensation more closely with Unicycive’s future share performance.
Unicycive Therapeutics, Inc. reported that CFO John Townsend received a grant of 169,500 restricted stock units as equity compensation. These RSUs are payable solely in common stock and carry no cash exercise price.
The RSU award vests in three equal installments, with one-third of the shares vesting on each anniversary of the grant date over three years, conditioned on Townsend’s continued service with the company. Following this grant, he holds 169,500 derivative securities linked to common stock, aligning part of his compensation with future share performance.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sandeep Laumas received two restricted stock unit grants as equity compensation. One RSU award covers 42,100 underlying shares of common stock and will vest in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service.
The second, annual RSU award covers 84,200 underlying shares of common stock and will vest in full one year after the grant date, also subject to his continued service with the company. Following these grants, his reported direct RSU holdings tied to these awards total 126,300 and 84,200 units, respectively.